GenCanna continues to bet on the future of UK bulk and white label CBD products with the purchase of another company specialising in those areas.
The Kentucky company has continued its return from bankruptcy by acquiring CBD Capital, a provider of CBD distillate, isolate and water-soluble bulk ingredients as well as white and private label services to the UK, the EU and markets worldwide.
It follows the earlier acquisition of UK-based Taylor Mammon, another major player in the same field.
...
Need help?
Contact a sales representative right now and don’t wait
“ GenCanna’s latest white label purchase deepens penetration of UK and Europe ”
Buy report request information:
“ GenCanna’s latest white label purchase deepens penetration of UK and Europe ”
GenCanna continues to bet on the future of UK bulk and white label CBD products with the purchase of another company specialising in those areas.
The Kentucky company has continued its return from bankruptcy by acquiring CBD Capital, a provider of CBD distillate, isolate and water-soluble bulk ingredients as well as white and private label services to the UK, the EU and markets worldwide.
It follows the earlier acquisition of UK-based Taylor Mammon, another major player in the same field.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.
Benefits of subscription plans:
Stay informed of any legal and market change in the sector that impacts your organization
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Need help?
Contact a sales representative right now and don’t wait
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.
